

Measurement of Fractional Whole-Body Gluconeogenesis in Humans From Blood Samples Using ^2H Nuclear Magnetic Resonance Spectroscopy

O. Kunert,¹ H. Stingl,² E. Rosian,¹ M. Krššák,² E. Bernroider,² W. Seebacher,¹ K. Zangger,¹ P. Staehr,³ V. Chandramouli,⁴ B.R. Landau,⁴ P. Nowotny,² W. Waldhäusl,² E. Haslinger,¹ and M. Roden²

Several problems limit quantification of gluconeogenesis. We applied *in vitro* ^2H -nuclear magnetic resonance (NMR) spectroscopy to simultaneously measure ^2H in all glucose carbons for direct assessment of gluconeogenesis. This method was compared with ^2H measurement in carbons 5 and 2 using gas chromatography-mass spectrometry (hexamethylenetetramine [HMT]) and with *in vivo* ^{13}C magnetic resonance spectroscopy (MRS). After 14 h of fasting, and following $^2\text{H}_2\text{O}$ ingestion, blood was obtained from nine healthy and seven type 2 diabetic subjects. Glucose was purified, acetylated, and analyzed for ^2H in carbons 1–6 with ^2H -NMR. Using 5:2 ratios, gluconeogenesis increased ($P < 0.05$) over time and mean gluconeogenesis was lower in control subjects than in type 2 diabetic patients (63 ± 3 vs. $75 \pm 2\%$, $P < 0.01$). ^{13}C -MRS revealed higher hepatic glycogenolysis in control subjects (3.9 ± 0.4 vs. $2.3 \pm 0.2 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) yielding mean contribution of gluconeogenesis of 65 ± 3 and $77 \pm 2\%$ ($P < 0.005$). Measurement of gluconeogenesis by ^2H -NMR correlated linearly with ^{13}C -MRS ($r = 0.758$, $P = 0.0007$) and HMT ($r = 0.759$, $P = 0.0007$). In an additional protocol, ^2H enrichments demonstrated a fast decline of gluconeogenesis from ~ 100 to $\sim 68\%$ ($P < 0.02$) within 4 h of galactose infusion after 40–44 h of fasting. Thus, *in vitro* ^2H -NMR offers an alternative approach to determine fractional gluconeogenesis in good agreement with standard methods and allows monitoring of rapid metabolic alterations. *Diabetes* 52:2475–2482, 2003

From the ¹Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria; the ²Division of Endocrinology and Metabolism, Department of Internal Medicine III, University of Vienna, Vienna, Austria; the ³Department of Medical Endocrinology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; and the ⁴Department of Medicine and Biochemistry, Case Western Reserve University, Cleveland, Ohio.

Address correspondence and reprint requests to Michael Roden, Division of Endocrinology and Metabolism, Department of Internal Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. E-mail: michael.roden@akh-wien.ac.at.

Received for publication 19 January 2003 and accepted in revised form 17 July 2003.

O.K. and H.S. contributed equally to this work.

EGP, endogenous glucose production; FFA, free fatty acid; HMT, hexamethylenetetramine; MRS, magnetic resonance spectroscopy; NMR, nuclear magnetic resonance; PAG, D-pentaacetylglucose; PEP, phosphoenolpyruvate.

© 2003 by the American Diabetes Association.

In type 2 diabetic patients, gluconeogenesis primarily accounts for increased endogenous glucose production (EGP) and fasting plasma glucose concentrations (1). Previous methods for measuring gluconeogenesis yielded a wide range of estimates in humans, which may relate to biochemical limitations of those methods (2–5). Gluconeogenesis can be also calculated from the difference between the rates of EGP determined with $[6\text{-}^3\text{H}]\text{glucose}$ and of liver glycogen breakdown determined by *in vivo* ^{13}C -nuclear magnetic resonance spectroscopy (MRS) (1,6). This method quantifies rates of gluconeogenesis but requires patients to lie for hours within a magnet (7). An alternative method is based on incorporation of ^2H into glucose after $^2\text{H}_2\text{O}$ administration (8). In humans, gluconeogenesis can be calculated from ^2H enrichments in hexamethylenetetramine (HMT) derived from blood glucose measured with gas chromatography-mass spectrometry (9,10). Briefly, ^2H is incorporated into position 3 of phosphoenolpyruvate (PEP) during the equilibration of pyruvate with alanine and via conversion of the pyruvate to oxaloacetate to the extent it equilibrates with fumarate. The carbon at position 3 of PEP becomes carbon 6 of glucose. ^2H is incorporated into position 2 of glyceraldehyde-3-P via its isomerization with dihydroxyacetone-3-P and via hydration of PEP to 2-phosphoglycerate. During glycerol conversion, ^2H is introduced at position 2 of glyceraldehyde-3-P. Carbon two of glyceraldehyde-3-P becomes carbon 5 of glucose. Subsequently, position 2 of glucose is labeled with ^2H during both gluconeogenesis and glycogenolysis. Thus, the ratio of ^2H enrichment at position 5 to that at two of glucose represents the fractional contribution of gluconeogenesis to EGP (9,10). This method was shown to overcome limitations of previous methods in humans but requires extensive and time-consuming biochemical preparations.

Determination of 5:2 ratios by *in vitro* ^2H -NMR spectroscopy using monoacetone glucose (11–14) has been reported. Biochemical short-comings of previous approaches and invasive or time-consuming procedures can be avoided by this method. In the present study, 5:2 ratios were obtained by an alternative approach applying *in vitro* ^2H -NMR on a glucopyranosyl bromide derivative. The estimates of gluconeogenesis were compared with both *in vivo* ^{13}C -MRS and the HMT method.

This method was tested under both the usually applied

conditions of continuously increasing gluconeogenesis (i.e., overnight and prolonged fasting) and the conditions of rapidly decreasing fractional contribution of gluconeogenesis to EGP (i.e., intravenous galactose infusion after prolonged fasting). In the prolonged fasted state, gluconeogenesis almost completely accounts for EGP, but since galactose in liver is converted to glucose via glucose-1-P and glucose-6-P (the same intermediates as in glycogenolysis), galactose administration is expected to cause a rapid fall in the contribution of gluconeogenesis to EGP.

RESEARCH DESIGN AND METHODS

Clinical protocols

Study on the evaluation of the method. Nine healthy male volunteers (control subjects) (age range 22–28 years, BMI $22.6 \pm 0.5 \text{ kg/m}^2$, and HbA_{1c} $5.1 \pm 0.1\%$) and seven well-controlled type 2 diabetic patients (age range 49–62 years, BMI $26.1 \pm 0.9 \text{ kg/m}^2$, and HbA_{1c} $7.1 \pm 0.2\%$) were on an isocaloric diet (>50% carbohydrates) and refrained from physical exercise for ≥ 3 days. The patients discontinued oral hypoglycemic agents at least 3 days before the study. None of them suffered from diabetes-related complications. All participants gave informed written consent to the protocols, which were approved by the institutional ethics board, and all participants participated in two protocols in randomized order. They ingested a liquid meal (60% carbohydrate, 20% protein, and 20% fat) at 6:00 P.M. (15) and fasted overnight. On day 1, they drank 5 g $^2\text{H}_2\text{O}$ (99.9% ^2H ; Cambridge Isotope Laboratory, Andover, MA) per kilograms of body water divided into four doses spaced 30 min from 6:00 (12 h of fasting) to 7:30 A.M. (10,16). Blood was drawn at 6:00, 8:00 (14 h of fasting), and 10:00 (16 h of fasting) A.M. and at the end of the study at noon (18 h of fasting). The volume of blood samples was 30 ml per time point and was doubled in some experiments for determination of the precision of the method. No side effects of $^2\text{H}_2\text{O}$ were observed.

On another day, subjects first received an intravenous bolus, adjusted for plasma glucose concentration, and from 6:00 until noon (18 h of fasting) they received a continuous infusion of D-[6,6- $^2\text{H}_2$]glucose (99% enriched; Cambridge Isotope Laboratory). Simultaneously, liver glycogen concentration was monitored by *in vivo* ^{13}C -MRS from 12.5–13.5 and 15–16 h and at the end of the study (17–18 h of fasting). Blood samples were chilled and centrifuged, and supernatants were stored at -20°C .

Study on the effect of galactose. Three healthy male subjects (age range 24–25 years, BMI $23.7 \pm 2.0 \text{ kg/m}^2$, and HbA_{1c} $5.0 \pm 0.1\%$) participated in this protocol, which was identical to the first study including ingestion of $^2\text{H}_2\text{O}$ until completion of day 1, but they were continued for a total of 44 h of fasting. Throughout the study, subjects had free access to water containing 0.5% $^2\text{H}_2\text{O}$ to maintain isotopic equilibrium in body water. At 40 h of fasting, galactose (9 g/h) was intravenously infused for 4 h. Subjects were also infused with D-[6,6- $^2\text{H}_2$]glucose (99% enriched; Cambridge Isotope Laboratory), and liver glycogen concentrations were measured from 37.5 until 44 h of fasting. Blood samples were obtained at 16, 18, 40, 42, and 44 h and treated as above.

Preparation of blood glucose. Blood (~ 30 ml) was diluted with equal volumes of water and deproteinized with $\text{ZnSO}_4/\text{Ba}(\text{OH})_2$. After lyophilization, plasma was purified on anion exchange column ($1.6 \times 10 \text{ cm}$) filled with Bio-Rad resins 4.5 g AG1-X8 (acetate form) and 4.0 g AG50W-X8 (proton form). The glucose was eluted with water, and glucose-containing fractions (~ 6 ml) were analyzed for glucose by glucose test sticks. In test-runs with pure glucose, a yield of close to 100% of the starting material was achieved. **α , β -D-pentaacetyl glucose.** Lyophilized glucose was dissolved in dry pyridine (6.7 μl pyridine/mg glucose) and incubated (0°C , 18 h) with acetic anhydride (4.6 μl /mg glucose). After dilution with five times the volume of water and lyophilization, a mixture of α - and β -D-pentaacetylglucose (PAG) was obtained.

2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide. The mixture of α - and β -PAG was dissolved in dry chloroform (10 μl /mg PAG), and hydrogen bromide (10 μl /mg PAG) dissolved in glacial acetic acid was added at 0°C . After 1.5 h incubation and the addition of the same volume of chloroform, the solution was washed five times with water. After lyophilization, 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide was obtained as a yellowish oil and dissolved in natural abundance benzene. ^1H spectra of the product were recorded in some samples and revealed a purity of the derivative of >95%.

1,2-5,6-di-O-isopropylidene- α -D-glucufuranose. Glucose was dissolved in dry acetone (0.35 ml/mg glucose), and anhydrous ZnCl_2 (5 mg/mg glucose) and concentrated phosphoric acid (0.5 μl /mg glucose) were added. After 18 h, Na_2CO_3 solution was added to precipitate zinc ions. 1,2-5,6-di-O-isopropylidene- α -D-glucufuranose was obtained by lyophilization of the supernatant and in natural abundance acetone.

In vitro ^2H -NMR. ^2H enrichments at positions 1, 2, 3, 4, 5, 6, and 6' were obtained from spectra that were acquired on a Varian Unity INOVA spectrometer (9.4 T, 400 MHz; 5-mm broad band probe) (Fig. 1). For determination of optimal acquisition times, various 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide derivatives were prepared from D-[5- ^2H]glucose (98% enriched in ^2H ; Omicron Biochemicals, South Bend, IN), D-[2- ^2H]glucose (98% enriched in ^2H ; Cambridge Isotope Laboratory), and perdeuterated glucose (98% enriched in ^2H ; Sigma Chemical, Perth, Australia). Signal intensities were not different for acquisition times between 1.5 and 3 s, which were used in all further experiments. To reduce line-broadening in unlocked mode occurring during acquisition of spectra for 5–20 h, the transmitter frequency was adjusted by the shift of the solvent resonance after each set of 2,048 transients. This yielded a resolution of 1.5 Hz, even after 36 h. All spectra were multiplied with an exponential window function of 1.5-Hz line broadening before Fourier transformation. Spectra were least-square fitted with Lorentzian lines using the Varian Vnmr deconvolution routine (17). The natural line widths of the glucose resonances were 7–8 Hz, whereas that of the solvent, benzene, was 3.6 Hz. Spectra were acquired at a temperature of 303 K. The percent contribution of gluconeogenesis to EGP was set to 100 times the ratio of ^2H enrichments at position 5 to that at carbon 2 (5:2) of blood glucose (10).

In vivo ^{13}C MRS. Subjects were lying within a magnet (3-T Medspec 30/80-DBX system; Bruker Medical, Ettlingen, Germany) using a 10-cm double-tuned $^1\text{H}/^{13}\text{C}$ circular coil (15,18). Spectra were acquired using a modified 1D inversion-based sequence (6) without ^1H decoupling (19). Glycogen concentrations were measured by integration of the carbon 1 glycogen doublet at 100.5 ppm using the same frequency bandwidth (± 300 Hz) for all spectra. Absolute quantification was performed by comparing the peak integral with that of a glycogen standard (6). Corrections for loading and sensitive volume of the coil were done. Liver volumes were measured in a 1.5-T Vision imager (Siemens, Germany) using a body array coil and in-phase and postphase multislice FLASH imaging sequences (15,18).

Gas chromatography-mass spectrometry. ^2H enrichments at positions 2 and 5 of blood glucose were determined by isolating the hydrogens in formaldehyde derivatized to HMT (9,10,20). Briefly, deproteinized blood samples were deionized by ion exchange, and the glucose was purified by high-performance liquid chromatography. Aliquots of glucose were converted to arabinol-5-P and ribitol-5-P and to xylose, which were oxidized with periodate to yield formaldehyde containing carbons 2 and 5 of glucose, respectively. The HMTs were assayed for ^2H enrichments by mass spectrometry using mass 141 for the enrichments at positions 2 and 5.

To assess EGP, ^2H enrichments in carbon 6 of glucose pentaacetate were assayed on a Hewlett-Packard 5,890 gas chromatograph interfaced to a Hewlett-Packard 5971A mass selective detector (15,18). $M + 2$ enrichments were measured from the mass-to-charge ratio of 202:200 of the fragment ion consisting of carbons 2–6. Rates of EGP were calculated by using the Steele equations for non-steady-state conditions (21).

^2H enrichments in plasma water were measured by Metabolic Solutions (Nashua, NH) using an isotopic ratio mass spectrometer.

Metabolites and hormones. Plasma glucose was measured on a Glucose Analyzer II (Beckman, Fullerton, CA). Plasma free fatty acids (FFAs) (Wako Chemical, Neuss, Germany) (intra- and inter-assay coefficient of variation [CV] <6%), lactate (CV 3.3%), and β -hydroxy-butyrate (CV <9%) were quantified enzymatically. Plasma insulin, C-peptide, glucagon, and cortisol were measured by radioimmunoassay as described (15,16,22).

Data analysis. Data are presented as means \pm SE unless otherwise stated. Linear regression analysis was performed by least-square fitting of data. One-way ANOVA with Bartlett's test for equal variances and paired Student's *t* tests were used as appropriate.

RESULTS

Study on the evaluation of the method

Metabolites and hormones. Plasma glucose was higher in type 2 diabetic patients ($9.9 \pm 1.1 \text{ mmol/l}$) than in control subjects ($5.4 \pm 0.1 \text{ mmol/l}$; $P < 0.005$). Type 2 diabetic patients also exhibited increased plasma concentrations of FFA (0.48 ± 0.03 vs. $0.35 \pm 0.03 \text{ mmol/l}$; $P < 0.001$) and lactate (1.26 ± 0.12 vs. $0.50 \pm 0.09 \text{ mmol/l}$; $P < 0.01$) but not β -hydroxy-butyrate (0.12 ± 0.01 vs. $0.11 \pm 0.01 \text{ mmol/l}$). Mean plasma insulin (60 ± 12 vs. $39 \pm 3 \text{ pmol/l}$) and C-peptide (749 ± 149 vs. $484 \pm 44 \text{ pmol/l}$) were higher ($P < 0.005$) in type 2 diabetic patients than in control subjects. Mean plasma glucagon (81 ± 10 vs. $70 \pm 5 \text{ pg/ml}$), cortisol (337 ± 36 vs. $375 \pm 37 \text{ nmol/l}$), and




FIG. 1. ^2H -NMR spectra of 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide obtained in a single blood sample of one healthy volunteer at 14, 16, and 18 h of fasting upon ingestion of $^2\text{H}_2\text{O}$ (5 g/kg body water).

growth hormone (1.8 ± 0.7 vs. 1.0 ± 0.4 $\mu\text{g/l}$) were comparable between type 2 diabetic patients and control subjects. All of these parameters were not different between both days.

Precision of in vitro ^2H -NMR. After 10 h of accumulation of spectra in a sample containing 91 mg 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide, the signal-to-noise (s/n) ratio of the smallest peak, i.e., resonance at carbon 6', was ~ 20 for acquisition times of 3 s (12,000 transients).

To assess the reproducibility, spectra were recorded

under identical conditions yielding an SD $< 3\%$ for 5:2 ratios. At lowest s/n ratio of ~ 10 (for the resonance at carbon 6'), the SD of the 5:2 ratio increased to $\leq 6\%$.

To estimate the accuracy of the NMR measurements as a function of the s/n ratio, 2 mg 2,4,6-tetra-O-acetyl- α -D-[2- ^2H]glucopyranosyl bromide were dissolved in natural abundance benzene, and four sets of ^2H spectra were recorded with increasing numbers of transients (4, 16, 32, 64, 128, 256), giving a total of 24 measurements. The s/n ratio of the glucose signal ranged between 8 and 64 (4 and

TABLE 1

^2H enrichments (%) at carbons 1, 3, 4, 5, and 6 relative to those at carbon 2 in plasma glucose of healthy subjects ($n = 9$) and type 2 diabetic subjects ($n = 7$) between 14 and 18 h of fasting after ingestion of 5 g $^2\text{H}_2\text{O}$ per kg body water

	1/2	3/2	4/2	5/2	6/2
Control subjects					
14 h	73 \pm 4	49 \pm 8	75 \pm 4	51 \pm 5	43 \pm 3
16 h	67 \pm 5	42 \pm 6	73 \pm 7	65 \pm 4	48 \pm 6
18 h	81 \pm 3	53 \pm 6	94 \pm 6	73 \pm 5	46 \pm 3
14–18 h	74 \pm 3	49 \pm 6	81 \pm 4	63 \pm 3	46 \pm 3
Type 2 diabetic subjects					
14 h	81 \pm 3	43 \pm 3	73 \pm 3	62 \pm 2	44 \pm 4
16 h	81 \pm 5	42 \pm 4	85 \pm 6	75 \pm 3	47 \pm 3
18 h	84 \pm 2	49 \pm 2	88 \pm 3	87 \pm 2	51 \pm 3
14–18 h	82 \pm 3	45 \pm 2	82 \pm 3	75 \pm 2	47 \pm 3

Data are means \pm SEM.

256 transients). The ratios of the integrated peak areas as determined by deconvolution of the spectra were plotted as a function of the s/n ratios of the ^2H signal of benzene and yielded CVs within 2% if the s/n ratio exceeded a value of ~ 20 .

The precision of data processing was determined by integrating the ^2H peaks three times in two different samples, yielding a variance $< 2\%$.

Absolute enrichments were checked with solutions containing D-[5- ^2H]glucose and D-[2- ^2H]glucose giving a theoretical 5:2 ratio of 49.9%. The measured 5:2 ratios were $\sim 51.3\%$ (0.595/1.160) with in vitro ^2H -NMR and $\sim 50.5\%$ (0.489/0.969) with the HMT method.

Gluconeogenesis from in vitro ^2H -NMR

^2H enrichments in plasma water. After $^2\text{H}_2\text{O}$ ingestion, ^2H enrichments in plasma water were 0.49 \pm 0.03% at 14 h, 0.47 \pm 0.01% at 16 h, and 0.46 \pm 0.01% at 18 h of fasting.

^2H -NMR spectra. ^2H spectra of 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide exhibited well-resolved ^2H signals at positions 1, 2, 3, 4, and 6', whereas those at 5 and 6 were superimposed (Fig. 1). ^2H spectra of 3-O-acetyl-1,2- β -D-glucopyranosyl bromide allowed separation of signals at positions 6 and 6', whereas those at 2 and 5 overlapped. ^2H enrichments at positions 6 and 6' were identical (ratio at 6:6' 1.03 \pm 0.08). Thus, for the glucopyranosyl bromide derivative, the integral of the resonance at carbon 5 was obtained by subtracting the ^2H enrichments at position 6' from the combined resonances at carbons 5 and 6. This allowed us to quantify ^2H enrichments at each of the seven positions and to calculate ^2H incorporation into glucose. Because the glucopyranosyl bromide derivative is obtained in a yield of 75–95% in a simple two-step reaction, we used it as the compound of choice.

From the 5:2 ratios of ^2H enrichments, gluconeogenesis increased from ~ 62 and $\sim 51\%$ at 14 h to ~ 87 ($P < 0.001$) and $\sim 73\%$ ($P = 0.005$) at 18 h of fasting in type 2 diabetic patients and control subjects, respectively (Table 1, Fig. 2). Type 2 diabetic patients presented with higher gluconeogenesis than control subjects ($P < 0.01$). Mean gluconeogenesis over the whole study period (14–18 h fasting) was $\sim 75\%$ in type 2 diabetic patients and $\sim 63\%$ in control subjects. In both type 2 diabetic patients and control subjects, the 3:2 and 6:2 ratios were lower ($P < 0.001$), whereas the 1:2 and 4:2 ratios were higher ($P < 0.001$) than the 5:2 ratios (Table 1). Using the HMT method, the 5:2

ratios gave an estimate of gluconeogenesis of 60 \pm 3 and 50 \pm 3% at 16 h and 67 \pm 3% as well as 51 \pm 3% at 18 h in type 2 diabetic patients and control subjects ($P < 0.001$), respectively (mean 63 \pm 3 and 51 \pm 3%, $P < 0.005$ vs. NMR method) (Table 2).

Gluconeogenesis from in vivo ^{13}C MRS. Hepatic glycogen concentrations were lower ($P < 0.0001$) in type 2 diabetic patients at 12.5–13.5 h (210 \pm 8 vs. 244 \pm 6 mmol/l liver) (Fig. 2). In all individuals of both groups, glycogen declined linearly (type 2 diabetic patients $r^2 = 0.73 \pm 0.07$, $P < 0.01$; control subjects $r^2 = 0.85 \pm 0.04$, $P < 0.01$) and was also lower in type 2 diabetic patients at 17–18 h of fasting (175 \pm 7 vs. 197 \pm 6 mmol/l liver, $P < 0.0001$). Mean rates of glycogen breakdown were also lower in type 2 diabetic patients than in control subjects (2.3 \pm 0.2 vs. 3.9 \pm 0.4 $\mu\text{mol} \cdot \text{kg body wt}^{-1} \cdot \text{min}^{-1}$, $P < 0.005$) (Table 2). Rates of EGP were higher in type 2 diabetic patients (16.3 \pm 1.2 vs. 11.2 \pm 0.4 $\mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, $P < 0.001$) (Table 2). The difference between EGP and glycogenolysis gives the absolute rate of gluconeogenesis (7.9 \pm 0.6 and 7.2 \pm 0.5 $\mu\text{mol} \cdot \text{kg body wt}^{-1} \cdot \text{min}^{-1}$), which accounted for 85 \pm 2 and 65 \pm 3% of EGP, respectively ($P < 0.0005$ type 2 diabetic patients vs. control subjects) (Table 2). Individual data of body weight (type 2 diabetic patients 85 \pm 5 kg and control subjects 73 \pm 2 kg) and liver volume (1.62 \pm 0.04 and 1.59 \pm 0.04 l, respectively) were used to calculate rates of gluconeogenesis and glycogenolysis.

Estimates of the contributions of gluconeogenesis to EGP from in vitro ^2H -NMR correlated linearly with that from in vivo ^{13}C -MRS ($r = 0.757$, $P = 0.0007$) (Fig. 3). In vitro ^2H -NMR also linearly correlated with HMT measurements ($r = 0.759$, $P = 0.0007$). Finally, in vivo ^{13}C -MRS and HMT measurements were linearly related ($r = 0.713$, $P = 0.002$).

Study on the effect of galactose

Metabolites and hormones. Plasma glucose declined ($P < 0.05$) from 5.1 \pm 0.1 mmol/l at 12 h to 4.1 \pm 0.1 mmol/l at 40 h. Thereafter, plasma glucose rose by $\sim 24\%$ ($P < 0.01$) during galactose infusion (Fig. 4). Plasma insulin concentrations were 17 \pm 1 pmol/l at 40 h and 27 \pm 5 pmol/l at 44 h. During galactose infusion, plasma C-peptide increased from 245 \pm 35 to 428 \pm 59 pmol/l ($P < 0.05$). Plasma FFAs were 0.70 \pm 0.12 mmol/l at 12 h, 0.86 \pm 0.06 mmol/l at 40 h, and 0.73 \pm 0.08 mmol/l at 44 h.

Glycogen metabolism from in vivo ^{13}C MRS. Liver glycogen concentrations were 86 \pm 4 mmol/l liver at the




FIG. 2. Liver glycogen concentrations (A) determined by in vivo ^{13}C -MRS (* $P < 0.0001$ vs. basal, $\$P < 0.0001$ vs. healthy subjects) and percent gluconeogenesis (B) determined by in vitro ^2H -NMR (* $P < 0.05$ vs. basal, $\$P < 0.05$ vs. healthy subjects) in healthy volunteers ($n = 9$; ●) and well-controlled type 2 diabetic patients ($n = 7$; ▲) during 18 h fasting. Data are given as means \pm SE.

37- to 38-h fast and declined ($P < 0.005$) to 77 ± 3 mmol/l at 39–40 h (Fig. 4), giving rates of hepatic glycogenolysis of $59 \pm 12 \mu\text{mol} \cdot \text{liver}^{-1} \cdot \text{min}^{-1}$. EGP was $9.2 \pm 0.6 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ at 40 h so that gluconeogenesis measured by in vivo ^{13}C -MRS was $89 \pm 2\%$ at ~37–40 h of fasting. During galactose infusion, liver glycogen concentrations rose from 78 ± 9 mmol/l (~40–41 h) to 104 ± 11 (~41.5–42.5 h, $P < 0.0005$) and 109 ± 10 mmol/l (~43–44 h, $P < 0.0001$), giving rates of hepatic glycogen synthesis

of $3.1 \pm 0.6 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$. EGP remained constant during galactose infusion (mean $8.8 \pm 0.2 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$).

Gluconeogenesis from ^2H enrichments. Using the HMT method, gluconeogenesis contributed to EGP by $94 \pm 5\%$ at 40 h ($P < 0.005$ vs. 16 h $61 \pm 5\%$) and declined to $72 \pm 2\%$ (42 h, $P < 0.05$) and $69 \pm 6\%$ (44 h, $P < 0.005$) during galactose infusion. Using in vitro ^2H -NMR, gluconeogenesis contributed to EGP by $99 \pm 6\%$ at 40 h and declined to

TABLE 2

Summary of EGP, hepatic glycogenolysis, and gluconeogenesis in 7 type 2 diabetic and 9 nondiabetic volunteers

	Type 2 diabetic subjects		Control subjects	
	Absolute rate ($\mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$)	Fraction of EGP (%)	Absolute rate ($\mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$)	Fraction of EGP (%)
EGP	$16.3 \pm 1.2^*$	100	11.2 ± 0.4	100
Glycogenolysis	$2.3 \pm 0.2^*$	$15 \pm 2^*$	3.9 ± 0.4	35 ± 3
GNG (^{13}C -MRS)	$14 \pm 1.3^*$	$85 \pm 2^*\P$	7.3 ± 0.4	65 ± 3
GNG (^2H -NMR)	—	$75 \pm 2^*\P$	—	$63 \pm 3^*\P$
GNG (HMT)	—	$63 \pm 3^*$	—	51 ± 3

Data are means \pm SEM. Comparison of estimates of gluconeogenesis (GNG) as calculated from 5:2 ratios in plasma glucose measured with in vitro ^2H -NMR spectroscopy, from HMT and from the difference between EGP and hepatic glycogenolysis measured with in vivo ^{13}C -MRS. * $P < 0.01$ vs. control subjects $\P P < 0.005$ vs. HMT.




FIG. 3. Correlation of estimates of percent gluconeogenesis obtained by in vitro ^2H -NMR and in vivo ^{13}C -MRS in healthy subjects ($n = 9$; ●) and well-controlled type 2 diabetic patients ($n = 7$; ▲).

79 ± 2 and $70 \pm 3\%$ (44 h, $P < 0.02$) during galactose infusion (Fig. 4). Estimates for gluconeogenesis were not different between both methods.

DISCUSSION

In vitro ^2H -NMR has recently been used to measure ^2H incorporation from $^2\text{H}_2\text{O}$ in glucose from various natural sources. In one study (23), glucose, isolated from plants, was converted to 3,6-anhydro-1.2-O-isopropylidene- α -D-glucopyranose. That derivative exhibited all seven separated ^2H resonances at 61 MHz, but multiple preparation steps prevent its efficient application on a micro scale. In another study (12), glucose, isolated from rat plasma, was oxidized to its gluconate. ^2H at carbon 1 is lost during the conversion, and resolved signals are only obtained for carbons 2 and 3. The 3:2 ratio was then used to estimate gluconeogenesis. The same group reported fully resolved ^2H resonances employing monoacetone glucose (11) using body water enrichments of ^2H between 2.5–5% in rats. More recently, this method was used to estimate gluconeogenesis in humans at body water enrichments of 0.5% (13). We found our derivative to be easier to prepare and provide a higher overall yield. However, the resolution of monoacetone glucose allows the baseline separation of all ^2H resonances at 10 T, and the line width of NMR signals was slightly superior in our hands.

The present study also used ^2H enrichments of 0.5% in body water as reported previously in other studies in humans (9,10,13,16). These procedures make determination of ^2H enrichments at all carbons of glucose feasible at a safe dose of $^2\text{H}_2\text{O}$ in humans. Although the ^2H resonances at carbons 5 and 6 of glucose overlapped, identical ^2H enrichments at positions 6 and 6'—which is in agreement with studies in rats (11)—allowed us to calculate 5:2 ratios. Our estimates of gluconeogenesis are similar to those reported at 15 and 18.5 h of fasting (24) but somewhat higher than in other studies (2,9) using the HMT method. Measurements of gluconeogenesis by the HMT method and in vitro ^2H -NMR were linearly correlated, although the latter method gave higher estimates of 5:2 ratios. As both methods measure 5:2 ratios in blood glucose, no differences are to be expected. One potential

explanation for the higher estimates from in vitro ^2H -NMR could reside in the calculation of 5:2 ratios, which requires subtracting the peak area at position 6' from that at 5 and 6 in order to obtain the peak area at position 5. Although the peak areas at positions 6' and 6 of glucopyranosyl bromide were found to be identical, small variations in these peaks could affect the 5:2 ratios. Thus, the HMT method could be quantitatively more correct, whereas this ^2H -NMR method would be most useful for evaluating relative changes in the fractional enrichments. Nevertheless, both estimates are in the range of 50–65% observed after overnight fasting (2,6,16,18,24).

Interestingly, the 3:2 ratios gave lower ($P = 0.029$) estimates of gluconeogenesis than the 5:2 ratios, which is similar to findings in fasted rats (11). The differences between the 6:2 and 5:2 ratios were even greater (19%, $P < 0.001$) and similar to that reported for the HMT method (16–22% at 14–22 h of fasting) (9,10). The 6:2 ratio has been used for measuring gluconeogenesis (9) but gives an underestimation because 1) binding of ^2H at position 6 depends on the exchange of the hydrogens of pyruvate and alanine and of oxaloacetate and fumarate with those of water in their equilibrations before oxaloacetate's conversion to glucose, and 2) the conversion of glycerol to glucose does not result in binding of ^2H at position 6 (25). Assuming complete exchange of hydrogens in body water at the level of pyruvate (pyruvate alanine and oxaloacetate fumarate), the 6:2 ratios reflect gluconeogenesis from the level of PEP, and the difference of 5:2 and 6:2 ratios reflects gluconeogenesis from glycerol. Using the individual data at each time point, gluconeogenesis from glycerol contributes to EGP by 27 ± 4 and $19 \pm 4\%$ in type 2 diabetic patients and control subjects ($P = 0.05$), respectively. The estimates of the contribution of glycerol are somewhat higher than in previous reports (13,26). Nevertheless, in type 2 diabetic patients, the lower contribution of glycogen to EGP could be due to augmented gluconeogenesis from glycerol rather than from PEP, which was similar in type 2 diabetic patients and control subjects, as demonstrated by comparable 6:2 ratios (Table 1).

In contrast, the 1:2 ratio would have overestimated the contribution of gluconeogenesis to EGP, which is in

agreement with a previous study (25). That is presumably explained by a contribution of glycogenolysis to the ^2H at position 1 during short-term fasting because of equilibration of mannose-6-P with glucose-6-P via fructose-6-P (25).

To our knowledge, 4:2 ratios have not yet been compared with 5:2 ratios in humans in a similar experimental setup, i.e., after $^2\text{H}_2\text{O}$ ingestion. The 4:2 ratios were higher than the 5:2 ratios in both healthy and type 2 diabetic subjects, suggesting that this finding could be a constant phenomenon. With the equilibration at the triose-P level, one might expect that labeling at position 3 and 4 would approach that at position 5 but not exceed it.

Current limitations such as the large sample volume and long duration of spectra accumulation should be reduced by employing a custom-built NMR probe. With such equipment the costs of our method will be in the range of those of the HMT method but much less compared with in vivo ^{13}C MRS.

Our study demonstrates that with all methods used, the contribution of gluconeogenesis to EGP is also higher in well-controlled type 2 diabetic patients as previously dem-

onstrated for type 2 diabetic patients with moderate metabolic control by ^{13}C -MRS (1,27) and the HMT method (24,28). Likewise, EGP was elevated in type 2 diabetic patients, which is in line with the majority of studies (29,30). As glycogenolysis was decreased in type 2 diabetic patients, probably due to lower hepatic glycogen concentrations, augmented gluconeogenesis mainly explains the increased EGP in these patients.

The conversion of galactose to glucose serves as a surrogate for glycogenolysis, since the same pathway is followed in both processes, i.e., the galactose-1-P formed is converted to glucose-1-P and hence to glucose-6-P. The decline in the percent of contribution of gluconeogenesis to glucose production was the same, $\sim 30\%$ over the 4 h of galactose infusion, confirmed by either the HMT or ^2H -NMR method. Of the approximate $11.4 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ infused, $\sim 29\%$, i.e., $3.1 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, appears to have been deposited in liver glycogen and $\sim 23\%$ (fractional decrease in gluconeogenesis times EGP), i.e., $2.6 \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, was converted to glucose that entered the circulation. While the use of 5:2 ratios gives a measure of




FIG. 4. Plasma glucose concentrations (A) ($*P < 0.05$ vs. 40 h), liver glycogen concentrations (B) ($*P < 0.01$ vs. 40 h), and percent gluconeogenesis obtained from in vitro ^2H -NMR (C) ($*P = 0.02$ vs. 40 h) during infusion of galactose (9 g/h) in healthy volunteers ($n = 3$).

the fractional contribution of gluconeogenesis to glucose production, the increase in glycogen content cannot be taken as a measure of the contribution of gluconeogenesis to glycogen formation under these conditions (31), since the conversion of galactose to glycogen does not require glucose 6-P as an intermediate, i.e., galactose-1-P is converted to UDP-glucose and hence glycogen. Also, galactose may not be considered a gluconeogenic substrate, since its conversion to glucose requires only epimerization of its hydroxyl at position, while its carbon skeleton remains intact.

In conclusion, in vitro ²H-NMR offers an alternative valid approach to directly quantify gluconeogenesis because this method 1) correlates linearly with established methods such as the HMT method and in vivo ¹³C MRS, 2) can be effectively applied in type 2 diabetic patients, and 3) allows monitoring of rapid changes in glycogenolysis and gluconeogenesis in humans. This could be of clinical relevance for studying glucose metabolism and new therapeutic strategies for diabetes treatment.

ACKNOWLEDGMENTS

The studies were supported by the Austrian Science Foundation (P13213-MOB, P13722-MED to M.R., P13718-CHE to E.H.), Novo Nordisk (to W.W.), National Institutes of Health (RO1-DK-14507 to B.R.L.), Austrian National Bank (9127 to H.S. and M.R.), and the Austrian Academy of Sciences (427/1997 to H.S.).

We thank D. Weghuber and the lab of the Division of Endocrinology and Metabolism, University of Vienna, for technical assistance and E. Moser, PhD, and the Department of Radiology for support.

REFERENCES

- Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI: Increased rate of gluconeogenesis in type II diabetes mellitus: A ¹³C nuclear magnetic resonance study. *J Clin Invest* 90:1323-1327, 1992
- Landau BR: Quantifying the contribution of gluconeogenesis to glucose production in fasted human subjects using stable isotopes. *Proc Nutr Soc* 58:963-972, 1999
- Radziuk J, Lee WP: Measurement of gluconeogenesis and mass isotopomer analysis based on [U-¹³C]glucose. *Am J Physiol* 277:E199-E207, 1999
- Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. *N Engl J Med* 338:867-872, 1998
- Mao CS, Bassilian S, Lim SK, Lee WN: Underestimation of gluconeogenesis by the [U-¹³C₆]glucose method: effect of lack of isotope equilibrium. *Am J Physiol Endocrinol Metab* 282:E376-E385, 2002
- Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI: Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with ¹³C NMR. *Science* 254:573-576, 1991
- Roden M, Shulman GI: Applications of NMR spectroscopy to study muscle glycogen metabolism in man. *Annu Rev Med* 50:277-290, 1999
- Guo ZK, Lee WN, Katz J, Bergner AE: Quantitation of positional isomers of deuterium-labeled glucose by gas chromatography/mass spectrometry. *Anal Biochem* 204:273-282, 1992
- Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC: Use of ²H₂O for estimating rates of gluconeogenesis: application to the fasted state. *J Clin Invest* 95:172-178, 1995
- Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC: Contributions of gluconeogenesis to glucose production in the fasted state. *J Clin Invest* 98:378-385, 1996
- Jones JG, Sherry AD, Malloy CR: Analysis of ²H enrichment in all positions of plasma glucose by ²H-NMR spectroscopy following infusion of ²H₂O. *Proc Intl Soc Mag Reson Med* 8:876, 2000
- Jones JG, Carvalho RA, Sherry AD, Malloy CR: Quantitation of gluconeogenesis by ²H nuclear magnetic resonance analysis of plasma glucose following ingestion of ²H₂O. *Anal Biochem* 277:121-126, 2000
- Jones JG, Solomon MA, Cole SM, Sherry AD, Malloy CR: An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans. *Am J Physiol Endocrinol Metab* 281:E848-E856, 2001
- Jones JG, Merritt M, Malloy C: Quantifying tracer levels of ²H₂O enrichment from microliter amounts of plasma and urine by ²H-NMR. *Magn Reson Med* 45:156-158, 2001
- Bischof MG, Krssak M, Krebs M, Bernroider E, Stingl H, Waldhäusl W, Roden M: Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. *Diabetes* 50:392-398, 2001
- Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhäusl W, Shulman GI: Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. *Diabetes* 49:701-707, 2000
- Martin YL: A global approach to accurate and automatic quantitative analysis of NMR spectra by complex least-squares curve fitting. *J Magn Reson* 111:1-10, 1994
- Stingl H, Krssak M, Krebs M, Bischof MG, Nowotny P, Furnsinn C, Shulman GI, Waldhäusl W, Roden M: Lipid-dependent control of hepatic glycogen stores in healthy humans. *Diabetologia* 44:48-54, 2001
- Stingl H, Schnedl WJ, Krssak M, Bernroider E, Bischof MG, Lahousen T, Pacini G, Roden M: Reduction of hepatic glycogen synthesis and breakdown in patients with agenesis of the dorsal pancreas. *J Clin Endocrinol Metab* 87:4678-4685, 2002
- Schumann WC, Gastaldelli A, Chandramouli V, Previs SF, Pettiti M, Ferrannini E, Landau BR: Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H₂O administration. *Anal Biochem* 297:195-197, 2001
- Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann N Y Acad Sci* 82:420-430, 1959
- Stingl H, Raffesberg W, Nowotny P, Waldhäusl W, Roden M: Reduction of plasma leptin concentrations by arginine but not lipid infusion in humans. *Obes Res* 10:1111-1119, 2002
- Schleucher J, Vanderveer PJ, Markley JL, Sharkey TD: Intramolecular deuterium distribution reveal disequilibrium of chloroplast phosphoglucose isomerase. *Plant Cell Environ* 22:525-533, 1999
- Wajngot A, Chandramouli V, Schumann WC, Ekberg K, Jones PK, Efenic S, Landau BR: Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. *Metabolism* 50:47-52, 2001
- Chandramouli V, Ekberg K, Schumann WC, Wahren J, Landau BR: Origins of the hydrogen bound to carbon 1 of glucose in fasting: significance in gluconeogenesis quantitation. *Am J Physiol* 277:E717-E723, 1999
- Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE: Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. *Diabetes* 35:1326-1331, 1986
- Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. *Diabetes* 49:2063-2069, 2000
- Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E: Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. *Diabetes* 49:1367-1373, 2000
- Boden G, Chen X, Stein TP: Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. *Am J Physiol Endocrinol Metab* 280:E23-E30, 2001
- Radziuk J, Pye S: Quantitation of basal endogenous glucose production in type II diabetes: importance of the volume of distribution. *Diabetologia* 45:1053-1084, 2002
- Landau BR: Methods for measuring glycogen cycling. *Am J Physiol Endocrinol Metab* 281:E413-419, 2001